The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offer the potential to further optimize visual and anatomical outcomes for patients ...

ONL-1204 is under clinical development by ONL Therapeutics and currently in Phase II for Retinal Pigment Epithelial (RPE) Detachment. According to GlobalData, Phase II drugs for Retinal Pigment ...

InflammX Therapeutics has granted Bausch + Lomb an exclusive option to acquire the company, focusing on retinal disease therapies. The acquisition option is contingent upon achieving specified ...

As of April 2023, the ASRS Research and Safety in Therapeutics (ReST) Committee began tracking reports of IOI, some of which resulted in severe retinal vasculitis, occlusive retinal vasculopathy ...

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina ...

Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital and an Outlook Therapeutics Board member, commented, “The 3-month data from NORSE EIGHT provides additional evidence to confirm what ...

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina ...